Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Hepatoma Research is Scopus-indexed (Q3, CiteScore 3), WoS ESCI. Published by OAE Publishing Inc..
Checked against the index lists dated .
ISSN 2394-5079Verify ISSN ↗2454-2520Verify ISSN ↗
Publisher: OAE Publishing Inc.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Hepatology | 47 / 88 | 47th | Q3 |
| Oncology | 262 / 428 | 38th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2019–present, best quartile Q3, CiteScore 3.
Hepatoma Research is Q3 in Hepatology (rank 47 of 88) and Q3 in Oncology (rank 262 of 428), by CiteScore 2025.
Hepatoma Research is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3, which places it in quartile Q3 at the 47th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.455, quartile Q3, with an H-index of 19.
Hepatoma Research is published by OAE Publishing Inc. Its print ISSN is 2394-5079 and its online ISSN is 2454-2520.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Hepatoma Research has an h-index of 26 and a 2-year mean of 1.58 citations per paper (OpenAlex). Its Scopus CiteScore is 3, quartile Q3. On 2-year citations it ranks #44 of 87 Scopus journals in Hepatology.
Hepatoma Research published 29 papers in 2025; its busiest recent year was 2020 with 85. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 82 research articles (2024–2026), authors are most often from China (46.7%), Italy (12.8%) and United States (6.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.